SC
EUCR

Shay Capital’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Shay Capital’s Portfolio EUCR Stock Details EUCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-67,761
Closed -$663K – 710
2021
Q3 		$663K Sell
67,761
-7,140
-10% -$69.6K 0.09% 215
2021
Q2 		$737K Sell
74,901
-375,862
-83% -$3.7M 0.08% 205
2021
Q1 		$4.5M Buy
+450,763
New +$4.63M 0.46% 46

Other funds holding EUCR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
ECU
Eisler Capital (UK) London, United Kingdom $21.7B AUM 0.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Shay Capital's EUCR Position: Q4 2021 in Review

Shay Capital sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q4 2021, closing a stake of 67,761 shares — an estimated $663K sold.

Shay Capital first reported a position in EUCR in Q1 2021 and held it in 3 quarters. The position peaked at $4.5M in Q1 2021. 39 funds tracked by Wall St. Rank hold EUCR as of Q4 2021.

  • Shay Capital reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q4 2021 after selling out during the quarter.
  • Shay Capital sold 67,761 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q4 2021, an estimated $663K.
  • Shay Capital first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q1 2021 and held it in 3 quarters.
  • Shay Capital's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $4.5M in Q1 2021.
  • 39 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q4 2021.

Based on Shay Capital's 13F filing for Q4 2021, filed 14 Feb 2022.